Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin for first-line advanced biliary tract cancer
NL-OMON59428Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Pembrolizumab plus gemcitabine/cisplatin with Placebo plus gemcitabine/cisplatin (2 arms). Primary endpoint: Overall survival. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NL-OMON59428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59428.